Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

Abatacept reduces immune activity by enhancing the activity of CTLA-4, a checkpoint receptor that tamps down T cell activation. By turning off immune responses through this mechanism, Abatacept ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

This immune imbalance contributed to evasion of immune destruction and limited the efficacy of programmed cell death protein 1 (PD-1) blockade. Dual checkpoint blockade reprogrammed the immune ...